TELMISARTAN: A CARDIO-METABOLIC SARTAN

Nayan Dutta, Neeraj Tulara, Nilesh Banthia, P. Chakradhar, Pradeep Sreedhar

Abstract


Hypertension occurs approximately twice as frequently in patients with diabetes compared with patients without diabetes. Conversely, hypertensive persons are more likely to develop diabetes than normotensive persons. Besides, up to 75% of cardiovascular disease in patients with diabetes may be attributed to hypertension, leading to recommendations for more aggressive blood pressure control in persons with coexistent diabetes and hypertension1. Given the current pandemic of obesity and diabetes mellitus type 2 in both developed and developing countries, the usage of antihypertensive drugs with beneficial metabolic properties in the treatment of arterial hypertension becomes of great clinical challenge. ß -blockers and diuretics have been found to have a detrimental influence on insulin sensitivity and glucose metabolism, calcium channel blockers seem to be metabolically neutral, while angiotensin-converting enzyme inhibitors and angiotensin receptors blockers (ARBs) may improve metabolic profile2.


Keywords


TELMISARTAN, Hypertension, angiotensin receptors blockers (ARBs)

Full Text:

PDF

Refbacks

  • There are currently no refbacks.